A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon
Phase of Trial: Phase II/III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Safinamide (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Meiji Seika Pharma
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 According to an Eisai Co Ltd media release, based on the results of the study, Meiji plans to submit a marketing authorization application for safinamide in Japan during 2018.
- 01 Feb 2018 Primary endpoint has been met. (on time), as reported in an Eisai Co Ltd media release.